Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8⁺ T cells eradicates peritoneal metastases in mouse models

References

• Coccolini F, Gheza F, Lotti M, Virzì S, Iusco D, Ghermandi C, Melotti R, Baiocchi G, Giulini SM, Ansaloni L, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19(41):6979–16. doi:10.3748/wjg.v19.i41.6979.
   PubMed Web of Science ®Google Scholar
• Terzi C. Peritoneal carcinomatosis of gastrointestinal tumors: where are we now? World J Gastroenterol. 2014;20(39):14371–14380. doi:10.3748/wjg.v20.i39.14371.
   PubMed Web of Science ®Google Scholar
• van Baal J, van Noorden Cjf, Nieuwland R, Van de Vijver KK, Sturk A, van Driel Wj, Kenter GG, Lok CAR, van Noorden CJF, van Driel WJ. Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J Histochem Cytochem. 2018;66(2):67–83. doi:10.1369/0022155417742897.
   PubMed Web of Science ®Google Scholar
• Cortes-Guiral D, Hubner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):91. doi:10.1038/s41572-021-00326-6
   PubMed Web of Science ®Google Scholar
• Etzerodt A, Moulin M, Doktor TK, Delfini M, Mossadegh-Keller N, Bajenoff M, Sieweke MH, Moestrup SK, Auphan-Anezin N, Lawrence T. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med. 2020;217(4). doi:10.1084/jem.20191869.
   PubMed Web of Science ®Google Scholar
• Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019;216(1):176–194. doi:10.1084/jem.20181170.
   PubMed Web of Science ®Google Scholar
• Platell C, Cooper D, Papadimitriou JM, Hall JC. The omentum. World J Gastroenterol. 2000;6(2):169–176. doi:10.3748/wjg.v6.i2.169.
   PubMed Web of Science ®Google Scholar
• Koppe MJ, Nagtegaal ID, de Wilt Jh, Ceelen WP, de Wilt JHW. Recent insights into the pathophysiology of omental metastases. J Surg Oncol. 2014;110(6):670–675. doi:10.1002/jso.23681.
   PubMed Web of Science ®Google Scholar
• Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–1503. doi:10.1038/nm.2492.
   PubMed Web of Science ®Google Scholar
• Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol. 2006;169(5):1739–1752. doi:10.2353/ajpath.2006.051222.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hu JN, Luo N, Zhao J, Liu SC, Ma T, Yao YM. The essential involvement of the omentum in the peritoneal defensive mechanisms during intra-abdominal sepsis. Front Immunol. 2021;12:631609. doi:10.3389/fimmu.2021.631609.
   PubMed Web of Science ®Google Scholar
• Beelen RH. Role of omental milky spots in the local immune response. Lancet. 1992;339(8794):689. doi:10.1016/0140-6736(92)90857-y.
   PubMed Web of Science ®Google Scholar
• Liu M, Silva-Sanchez A, Randall TD, Meza-Perez S. Specialized immune responses in the peritoneal cavity and omentum. J Leukoc Biol. 2021;109(4):717–729. doi:10.1002/JLB.5MIR0720-271RR.
   PubMed Web of Science ®Google Scholar
• Meza-Perez S, Randall TD. Immunological Functions of the Omentum. Trends Immunol. 2017;38(7):526–536. doi:10.1016/j.it.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Bella A, Arrizabalaga L, Di Trani CA, Fernandez-Sendin M, Teijeira A, Russo-Cabrera JS, Melero I, Berraondo P, Aranda F. Omentum: friend or foe in ovarian cancer immunotherapy? Int Rev Cell Mol Biol. 2022;371:117–131. doi:10.1016/bs.ircmb.2022.04.017.
   PubMedGoogle Scholar
• Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, Bereder JM, Arvieux C, Boschetti G, Glehen O, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23(6):1971–1979. doi:10.1245/s10434-015-5081-3.
   PubMed Web of Science ®Google Scholar
• Gamboa AC, Winer JH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer. Cancers (Basel). 2019;11(11):1662. doi:10.3390/cancers11111662.
   PubMed Web of Science ®Google Scholar
• Malfroy S, Wallet F, Maucort-Boulch D, Chardonnal L, Sens N, Friggeri A, Passot G, Glehen O, Piriou V. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: risk factors for ICU admission and morbidity prognostic score. Surg Oncol. 2016;25(1):6–15. doi:10.1016/j.suronc.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med. 2007;5:66. doi:10.1186/1479-5876-5-66.
   PubMed Web of Science ®Google Scholar
• Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, Boutros C, Hanna N, Junghans RP. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 2016;23(5):142–148. doi:10.1038/cgt.2016.14.
   PubMed Web of Science ®Google Scholar
• Orr B, Mahdi H, Fang Y, Strange M, Uygun I, Rana M, Zhang L, Suarez Mora A, Pusateri A, Elishaev E, et al. Phase I trial combining chemokine-targeting with loco-regional chemoimmunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity. Clin Cancer Res. 2022;28(10):2038–2049. doi:10.1158/1078-0432.CCR-21-3659.
   PubMed Web of Science ®Google Scholar
• Thadi A, Khalili M, Morano WF, Richard SD, Katz SC, Bowne WB. Early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis. Vaccines (Basel). 2018;6(3). doi:10.3390/vaccines6030054.
   PubMed Web of Science ®Google Scholar
• Bella Á, Arrizabalaga L, Di Trani CA, Cirella A, Fernandez-Sendin M, Gomar C, Russo-Cabrera JS, Rodriguez I, Gonzalez-Gomariz J, Alvarez M, et al. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. Oncoimmunology. 2022;11(1):2098657. doi:10.1080/2162402X.2022.2098657.
   PubMed Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697–5706. doi:10.1158/0008-5472.CAN-11-0103.
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446. doi:10.4161/2162402X.2014.994446.
   PubMed Web of Science ®Google Scholar
• Hombach A, Barden M, Hannappel L, Chmielewski M, Rappl G, Sachinidis A, Abken H. IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. Mol Ther. 2022;30(2):593–605. doi:10.1016/j.ymthe.2021.10.011.
   PubMed Web of Science ®Google Scholar
• Koneru M, O’Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015;13(1):102. doi:10.1186/s12967-015-0460-x.
   PubMedGoogle Scholar
• Etxeberria I, Bolanos E, Quetglas JI, Gros A, Villanueva A, Palomero J, Sanchez-Paulete AR, Piulats JM, Matias-Guiu X, Olivera I, et al. Intratumor Adoptive Transfer of IL-12 mRNA transiently engineered antitumor CD8(+) T Cells. Cancer Cell. 2019;36(6):613–629 e7. doi:10.1016/j.ccell.2019.10.006.
   PubMed Web of Science ®Google Scholar
• Bella Á, Di Trani CA, Fernández-Sendin M, Arrizabalaga L, Cirella A, Teijeira Á, Medina-Echeverz J, Melero I, Berraondo P, Aranda F. Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. Cancers. 2021;13(5):963. doi:10.3390/cancers13050963.
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol. 1997;15(1):35–40. doi:10.1038/nbt0197-35.
   PubMed Web of Science ®Google Scholar
• Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Tureci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–4017. doi:10.1182/blood-2006-04-015024.
   PubMed Web of Science ®Google Scholar
• Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–2120. doi:10.1093/bioinformatics/btu170.
   PubMed Web of Science ®Google Scholar
• Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21. doi:10.1093/bioinformatics/bts635.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015;43(7):e47–e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (N Y). 2021;2(3):100141. doi:10.1016/j.xinn.2021.100141.
   PubMedGoogle Scholar
• Weiss JM, Davies LC, Karwan M, Ileva L, Ozaki MK, Cheng RY, Ridnour LA, Annunziata CM, Wink DA, McVicar DW. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. J Clin Invest. 2018;128(9):3794–3805. doi:10.1172/JCI99169.
   PubMed Web of Science ®Google Scholar
• Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol. 2002;169(12):6842–6849. doi:10.4049/jimmunol.169.12.6842.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ohdan H, Manilay JO, Sykes M. NK cell tolerance in mixed allogeneic chimeras. J Immunol. 2003;170(11):5398–5405. doi:10.4049/jimmunol.170.11.5398.
   PubMed Web of Science ®Google Scholar
• Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011;19(4):751–759. doi:10.1038/mt.2010.313.
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 2011;121(12):4746–4757. doi:10.1172/JCI58814.
   PubMed Web of Science ®Google Scholar
• Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM, Drew AF. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67(12):5708–5716. doi:10.1158/0008-5472.CAN-06-4375.
   PubMed Web of Science ®Google Scholar
• Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, et al. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell. 2021;39(7):973–988 e9. doi:10.1016/j.ccell.2021.05.006.
   PubMed Web of Science ®Google Scholar
• Liu Z, Gu Y, Chakarov S, Bleriot C, Kwok I, Chen X, Shin A, Huang W, Dress RJ, Dutertre C-A, et al. Fate mapping via ms4a3-expression history traces monocyte-derived cells. Cell. 2019;178(6):1509–1525 e19. doi:10.1016/j.cell.2019.08.009.
   PubMed Web of Science ®Google Scholar
• Bauvois B, Durant L, Laboureau J, Barthelemy E, Rouillard D, Boulla G, Deterre P. Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II. J Interferon Cytokine Res. 1999;19(9):1059–1066. doi:10.1089/107999099313299.
   PubMed Web of Science ®Google Scholar
• Amici SA, Young NA, Narvaez-Miranda J, Jablonski KA, Arcos J, Rosas L, Papenfuss TL, Torrelles JB, Jarjour WN, Guerau-de-Arellano M. CD38 is robustly induced in human macrophages and monocytes in inflammatory conditions. Front Immunol. 2018;9:1593. doi:10.3389/fimmu.2018.01593.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, Dianzani U, Stockinger H, Malavasi F. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol. 1998;160:395–402.
   PubMed Web of Science ®Google Scholar
• Kang J, Park KH, Kim JJ, Jo EK, Han MK, Kim UH. The role of CD38 in Fcgamma receptor (FcgammaR)-mediated phagocytosis in murine macrophages. J Biol Chem. 2012;287(18):14502–14514. doi:10.1074/jbc.M111.329003.
   PubMed Web of Science ®Google Scholar
• Zilber MT, Setterblad N, Vasselon T, Doliger C, Charron D, Mooney N, Gelin C. MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. Blood. 2005;106(9):3074–3081. doi:10.1182/blood-2004-10-4094.
   PubMed Web of Science ®Google Scholar
• Thomassen I, Lemmens VE, Nienhuijs SW, Luyer MD, Klaver YL, de Hingh IH. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas. 2013;42(1):72–75. doi:10.1097/MPA.0b013e31825abf8c.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198(4):569–580. doi:10.1084/jem.20030590.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188(2):277–286. doi:10.1084/jem.188.2.277.
   PubMed Web of Science ®Google Scholar
• McMullen JRW, Selleck M, Wall NR, Senthil M. Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. 2017;8(26):43481–43490. doi:10.18632/oncotarget.16480.
   PubMedGoogle Scholar
• Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90:2541–2548.
   PubMed Web of Science ®Google Scholar
• Di Trani CA, Cirella A, Arrizabalaga L, Fernandez-Sendin M, Bella A, Aranda F, Melero I, Berraondo P. Overcoming the limitations of cytokines to improve cancer therapy. Int Rev Cell Mol Biol. 2022;369:107–141. doi:10.1016/bs.ircmb.2022.05.002.
   PubMedGoogle Scholar
• Gomez-Aguado I, Rodriguez-Castejon J, Beraza-Millor M, Rodriguez-Gascon A, Del Pozo-Rodriguez A, Solinis MA. mRNA delivery technologies: toward clinical translation. Int Rev Cell Mol Biol. 2022;372:207–293. doi:10.1016/bs.ircmb.2022.04.010.
   PubMedGoogle Scholar
• Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, Feldman GM, Nishikomori R, O’Shea JJ. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci U S A. 2002;99(19):12281–12286. doi:10.1073/pnas.182618999.
   PubMed Web of Science ®Google Scholar
• Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Perez-Gracia JL, Rodriguez-Ruiz ME, Ponz-Sarvise M, Castanon E, Melero I. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15. doi:10.1038/s41416-018-0328-y.
   PubMed Web of Science ®Google Scholar
• Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22(2):237–246. doi:10.1038/cdd.2014.134.
   PubMed Web of Science ®Google Scholar
• Cao X, Lai SWT, Chen S, Wang S, Feng M. Targeting tumor-associated macrophages for cancer immunotherapy. Int Rev Cell Mol Biol. 2022;368:61–108. doi:10.1016/bs.ircmb.2022.02.002.
   PubMedGoogle Scholar
• Perales-Puchalt A, Svoronos N, Villarreal DO, Zankharia U, Reuschel E, Wojtak K, Payne KK, Duperret EK, Muthumani K, Conejo-Garcia JR, et al. IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. Oncoimmunology. 2019;8(1):e1515058. doi:10.1080/2162402X.2018.1515058.
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 2014;74(6):1789–1800. doi:10.1158/0008-5472.CAN-13-2729.
   PubMed Web of Science ®Google Scholar
• Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122(1):4–22. doi:10.1038/s41416-019-0650-z.
   PubMed Web of Science ®Google Scholar
• Starbeck-Miller GR, Xue HH, Harty JT. IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. J Exp Med. 2014;211(1):105–120. doi:10.1084/jem.20130901.
   PubMed Web of Science ®Google Scholar
• Mitchell TC, Hildeman D, Kedl RM, Teague TK, Schaefer BC, White J, Zhu Y, Kappler J, Marrack P. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol. 2001;2(5):397–402. doi:10.1038/87692.
   PubMed Web of Science ®Google Scholar
• Valenzuela JO, Hammerbeck CD, Mescher MF. Cutting edge: bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T cells. J Immunol. 2005;174(2):600–604. doi:10.4049/jimmunol.174.2.600.
   PubMed Web of Science ®Google Scholar
• Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity. 2010;32(1):79–90. doi:10.1016/j.immuni.2009.11.012.
   PubMed Web of Science ®Google Scholar
• Rosa FM, Fellous M. Regulation of HLA-DR gene by IFN-gamma. Transcriptional and post-transcriptional control. J Immunol. 1988;140:1660–1664.
   PubMed Web of Science ®Google Scholar
• Martin-Otal C, Navarro F, Casares N, Lasarte-Cia A, Sanchez-Moreno I, Hervas-Stubbs S, Lozano T, Lasarte JJ. Impact of tumor microenvironment on adoptive T cell transfer activity. Int Rev Cell Mol Biol. 2022;370:1–31. doi:10.1016/bs.ircmb.2022.03.002.
   PubMedGoogle Scholar
• Louwe PA, Badiola Gomez L, Webster H, Perona-Wright G, Bain CC, Forbes SJ, Jenkins SJ. Recruited macrophages that colonize the post-inflammatory peritoneal niche convert into functionally divergent resident cells. Nat Commun. 2021;12(1):1770. doi:10.1038/s41467-021-21778-0.
   PubMed Web of Science ®Google Scholar
• Alam SM, Travers PJ, Wung JL, Nasholds W, Redpath S, Jameson SC, Gascoigne NR. T-cell-receptor affinity and thymocyte positive selection. Nature. 1996;381(6583):616–620. doi:10.1038/381616a0.
   PubMed Web of Science ®Google Scholar
• Uchtenhagen H, Abualrous ET, Stahl E, Allerbring EB, Sluijter M, Zacharias M, Sandalova T, van Hall T, Springer S, Nygren PA, et al. Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptides. Eur J Immunol. 2013;43(11):3051–3060. doi:10.1002/eji.201343456.
   PubMed Web of Science ®Google Scholar
• Tan TCJ, Knight J, Sbarrato T, Dudek K, Willis AE, Zamoyska R. Suboptimal T-cell receptor signaling compromises protein translation, ribosome biogenesis, and proliferation of mouse CD8 T cells. Proc Natl Acad Sci U S A. 2017;114(30):E6117–E6126. doi:10.1073/pnas.1700939114.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–5458. doi:10.4049/jimmunol.1490019.
   PubMed Web of Science ®Google Scholar
• Di Trani CA, Fernandez-Sendin M, Cirella A, Segues A, Olivera I, Bolanos E, Melero I, Berraondo P. Advances in mRNA-based drug discovery in cancer immunotherapy. Expert Opin Drug Discov. 2022;17(1):41–53. doi:10.1080/17460441.2021.1978972.
   PubMed Web of Science ®Google Scholar
• Pohl-Guimaraes F, Hoang-Minh LB, Mitchell DA. RNA-electroporated T cells for cancer immunotherapy. Oncoimmunology. 2020;9(1):1792625. doi:10.1080/2162402X.2020.1792625.
   PubMedGoogle Scholar
• Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277–283. doi:10.1016/s1470-2045(03)01074-x.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell Therapy. N Engl J Med. 2016;375(26):2561–2569. doi:10.1056/NEJMoa1610497.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Riviere I, Solomon SB, Rusch VW, O’Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 2021;11(11):2748–2763. doi:10.1158/2159-8290.CD-21-0407.
   PubMed Web of Science ®Google Scholar
• Cirella A, et al. Novel strategies exploiting interleukin-12 in cancer immunotherapy. Pharmacol Ther. 2022: 108189.
   Google Scholar